Royal Bank of Canada’s Alexion Pharmaceuticals ALXN Stock Holding History

Royal Bank of Canada’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-19,400	Closed	-$2.22M	–	7445
2020 Q3	$2.22M	Buy	+19,400	New	+$2.09M	﹤0.01%	2604
2020 Q2	–	Sell	-19,900	Closed	-$1.79M	–	7089
2020 Q1	$1.79M	Buy	+19,900	New	+$1.95M	﹤0.01%	2571
2018 Q3	–	Sell	-6,000	Closed	-$745K	–	7101
2018 Q2	$745K	Sell	6,000 -5,900	-50%	-$690K	﹤0.01%	3462
2018 Q1	$1.33M	Buy	+11,900	New	+$1.42M	﹤0.01%	2967
2017 Q4	–	Sell	-45,000	Closed	-$6.31M	–	7080
2017 Q3	$6.31M	Hold	45,000	–	–	﹤0.01%	1842
2017 Q2	$5.47M	Buy	+45,000	New	+$5.24M	﹤0.01%	1888
2016 Q2	–	Sell	-27,000	Closed	-$3.76M	–	6608
2016 Q1	$3.76M	Sell	27,000 -3,000	-10%	-$440K	﹤0.01%	2001
2015 Q4	$5.72M	Buy	30,000 +20,000	+200%	+$3.49M	﹤0.01%	1777
2015 Q3	$1.56M	Buy	+10,000	New	+$1.82M	﹤0.01%	2467
2013 Q3	–	Sell	-10,000	Closed	-$922K	–	6326
2013 Q2	$922K	Buy	+10,000	New	+$964K	﹤0.01%	2645

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Royal Bank of Canada's ALXN Position: Q3 2021 in Review

Royal Bank of Canada sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 831,958 shares — an estimated $153M sold.

Royal Bank of Canada first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $153M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Royal Bank of Canada reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Royal Bank of Canada sold 831,958 Alexion Pharmaceuticals shares in Q3 2021, an estimated $153M.
Royal Bank of Canada first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
Royal Bank of Canada's Alexion Pharmaceuticals position peaked at $153M in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Royal Bank of Canada's 13F filing for Q3 2021, filed 15 Nov 2021.